Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new clinical, biomarker and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), have been accepted for presentation at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21-23, 2026, in Toronto, Canada. All accepted abstracts will be published in the online supplement of the Multiple Sclerosis Journal and made available through the MSToronto2026 website, event app, and digital platform. Additionally, members of the Immunic team will attend the conference and host meetings. The team will be available throughout the event at booth #516.